The Renal HCL Study

This world first multi-site trial utilizes next generation hybrid closed loop insulin pump therapy in patients living with diabetes and advanced renal disease

Patients living with both advanced renal disease and diabetes can often
struggle with optimizing glycaemic control.

This trial utilizes the Medtronic MiniMed 780G system in patients
with type 1 and type 2 diabetes with advanced renal disease including
those on haemo dialysis and peritoneal dialysis, contrasted against
their usual care procedures.

By applying an artificial pancreas to automate insulin delivery and continuous
glucose monitoring using  the MiniMed 780G system, this study seeks to help
alleviate the mental, emotional and physical burdens attached to patients and
comparing  their usual care.

Become a participant!

Are you:
-Age 18-75yrs
-Living with Type 1 or Type 2 Diabetes
-Using either multiple daily injections of insulin or insulin pump therapy without automated insulin delivery
-Suffering from renal disease which falls into one of three categories:
1.) eGFR 15-45
2.) On peritoneal dialysis
3.) On haemodialysis
-Not on any other diabetes medications other than Metformin of GLP1 analogues (Ozempic, Trulicity)
-Have a smartphone with data plan

Then you may be perfect for this world first study

Meet Kim Henshaw who is a participant in type 1 diabetes technology research at the DTRG. Watch Kim explain what it means to her to be a participant in this important area of research.

Get involved

Please contact the Research Group Leader to discuss your options.